Research programme: autoimmune/inflammatory disorders - Amgen/MedImmune

Drug Profile

Research programme: autoimmune/inflammatory disorders - Amgen/MedImmune

Latest Information Update: 22 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; Cambridge Antibody Technology
  • Developer Amgen
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Inflammation

Most Recent Events

  • 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
  • 05 Jan 2004 Amgen and Cambridge Antibody Technology have restructured their antibody development agreement
  • 24 Jul 2002 Immunex has been acquired by, and merged into, Amgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top